← Back to Search

Alcohol Dehydrogenase Inhibitor

Disulfiram for Coronavirus (DISCO Trial)

Phase 2
Waitlist Available
Led By Sulggi A Lee, MD PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 and day 31
Awards & highlights

Summary

This trial is testing Disulfiram, a drug used to treat alcohol dependence, to see if it can help people with mild to moderate COVID-19. The drug might work by stopping the virus and reducing inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder and has shown potential in reducing the incidence and severity of COVID-19.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 and day 31
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 and day 31 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Immunologic Impact of 5 Days of Disulfiram, as Measured by the Fold-change in Plasma Levels of Pro-inflammatory Cytokines (e.g, Interleukin 6, Interleukin 1-beta, Etc.).
Secondary outcome measures
Change in COVID-19 Symptom Severity Score as Assessed by a 5-point Adapted Somatic Symptom Severity Score (SSS-8)
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Virologic Impact of 5 Days of Disulfiram, as Measured by the Change in Copies of SARS-CoV-2 Virus Per mL Between Baseline and Day 31.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DisulfiramExperimental Treatment1 Intervention
This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
Group II: PlaceboPlacebo Group1 Intervention
This study will provide placebo comparator for disulfiram. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Disulfiram
2008
Completed Phase 4
~1300

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,528 Previous Clinical Trials
15,242,621 Total Patients Enrolled
Sulggi A Lee, MD PhDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
19 Total Patients Enrolled
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top